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Translational Relevance
The presence of common genetic variation can refine prediction of patient outcome for colorectal cancer and help guide the management and risk assessment for individual patients.
This study suggests that inflammatory pathway-associated genetic variation may possibly be useful for improving outcome prediction for colorectal cancer patients. These results improve our understanding of colorectal cancer progression, confirming that key cellular pathways involved in colorectal cancer incidence also play a role in disease progression. Identified genes provide a good starting point for further research and potential targets for colorectal cancer therapy, including pharmacogenetic research on COX-inhibitors.
Introduction
Inflammation has consistently been associated with colorectal cancer development and prognosis in clinic and population studies. 1, 2 The role of inflammation in prognosis may be mediated through influences on processes crucial for tumor progression, including metastasis and invasion. [3] [4] [5] Medications that inhibit inflammation such as non-steroidal anti-inflammatory drugs (NSAIDs), which interact with the prostaglandin synthesis pathway, decrease the risk of colorectal neoplasia. [6] [7] [8] Consistent with inflammation's role not only in cancer development but also cancer progression, NSAIDs have also been associated in large, population-based studies with improved survival of colorectal cancer patients.
9-11
The prostaglandin synthesis pathway is critical for regulation of inflammatory processes and plays a well-defined role in colorectal carcinogenesis. 12, 13 Prostaglandin H synthases (COX-1 and COX-2) are pivotal enzymes in this pathway; 14, 15 upregulation of prostaglandins results in cellular proliferation, angiogenesis, and increased cellular motility. [16] [17] [18] The nuclear factor kappa B (NFκB) pathway represents another important pro-inflammatory pathway associated with colorectal cancer; NFκB is a transcription factor with multiple targets involved in inflammatory signaling and carcinogenesis, including prostaglandin synthases. [19] [20] [21] [22] The NFκB transcription factor plays a role not only in regulating cellular growth signals but also in regulating apoptosis and the survival of cancer cell populations. 23, 24 6 involved in the prostaglandin synthesis pathway in relation to colorectal cancer survival.
However, multiple studies have noted that variation in genes encoding both prostaglandin synthases and the NFκB transcription factor is associated with colorectal cancer risk. [26] [27] [28] [29] We therefore hypothesized that variation in these important inflammation-associated genes would affect the survival of colorectal cancer patients.
We examined SNPs in genes involved in both the prostaglandin synthesis pathway (PTGS1=COX-1, PTGS2=COX-2, MRP4) and the NFκB pathway (NFκB, IκBKβ) in relation to colorectal cancer survival among patients identified from the population-based Seattle Colon
Cancer Family Registry. This investigation represents one of the first descriptions of the relationship between inherited genetic polymorphisms and survival after a diagnosis of colorectal cancer. recognizing at the same time that a certain percentage are false positives. We generated a list of noteworthy SNPs at both the FDR 50% and FDR 25% levels for the five genes investigated.
Materials and Methods

Results
After an average of 6.5 years (SD=3.1 years) of follow-up after colorectal cancer diagnosis, 153 deaths from any cause were observed. Three quarters of the deaths among patients were due to colorectal cancer (n=115). Patients' ages at diagnosis ranged from 23 to 74, with ~10% of patients under the age of 40. A slightly larger proportion of deceased patients had microsatellite stable tumors and tumors located in the distal colon. As expected, patients diagnosed with localized tumors had much better overall survival compared to patients with advanced disease, with over 30% of deceased patients being diagnosed with advanced disease, as compared to only 5% of patient who remained alive at the end of study follow up (Table 1) .
Genetic variation in both PTGS-1 (COX-1) and IκBKβ was associated with colorectal cancer patient prognosis. These two genes had more SNPs with P -values <0.05 than expected by chance (more than 1 SNP for every 20 tested detected as statistically significant).
Additionally, of the five genes tested, only PTGS-1 and IκBKβ had SNPs that were noteworthy.
All SNPs noteworthy at the FDR 50% level are reported in Tables 2 and 3 . In contrast, patients with the minor allele for rs1213266 (G>A intron 9) had approximately 50% lower mortality compared to wild type patients (HR: 0.48; 95% CI 0.25-0.93) ( Table 2) .
Correction for multiple testing confirmed that genetic variation in PTGS-1 was associated with colorectal cancer survival, with six SNPs, including all SNPs noted above with P -values < 0.05, were noteworthy at the FDR 25% level; the expectation is that one quarter of these SNPs (less than 2) are false positives but that the remaining three quarters (at least 4) may in fact be associated with colorectal cancer patient survival.
Two of the nine SNPs in IκBKβ were statistically significantly associated with colorectal cancer mortality. Patients with the minor allele for rs11986055 (A>C intron 19) experienced less than half the mortality due to colorectal cancer compared to wild type patients (HR: 0.39; 95% CI 0.14-1.00) ( Table 3) . Estimates for R524Q were imprecise since only one patient was observed to carry the minor allele. Correction for multiple testing also indicated that genetic variation in IκBKβ was associated with colorectal cancer survival, with twoSNPs in IκBKβ noteworthy at the FDR 25% level.
When we restricted analyses to Caucasians only (n=381), we obtained similar results to those reported here. For both PTGS-1 and IκBKβ, all SNPs noteworthy when investigating colorectal cancer survival, except one, were also noteworthy when considering the outcome of death from any cause among patients. Effect estimates for the association between these SNPs and all-cause mortality were similar to those specific to colorectal cancer. For example, of the four SNPs in PTGS-1 that were statistically significantly associated with colorectal cancerspecific mortality, three were also statistically significantly associated with all-cause mortality (rs10306155: G>A intron 2, rs4836885: A>G intron 8, L237M: C>A exon 7) ( Table 2) . 
Discussion
This investigation is one of the first to explore the relationship between inherited genetic polymorphisms and colorectal cancer survival. Genetic variation in both PTGS-1 (COX-1) and IκBKβ was associated with an altered risk of mortality from colorectal cancer. Our confidence in these results is strengthened by the fact that specific polymorphisms in PTGS-1 and IκBKβ showed consistent statistical evidence of an association with colorectal cancer survival. Both genes had more SNPs with statistically significant associations than would be expected by IκBKβ has previously been identified as a crucial link between inflammatory processes and carcinogenesis in laboratory studies. 45, 46 This role in carcinogenesis is likely due to the inhibition of NFκB transcriptional activity by IκBKβ and the resulting resolution of NFκB-mediated inflammation in cells. 47, 48 Additionally, crucial downstream targets of the NFκB transcription factor include the prostaglandin synthases; 19, 22 disruptions in the regulation of NFκB through variation in IκBKβ could lead to altered PTGS-1 and PTGS-2 expression, resulting in variation in prostanoid production that could contribute to cancer progression.
Prior genome-wide scans investigating colorectal cancer incidence have not identified these genes as loci related to colorectal cancer initiation. However, investigation of the association between the top variants identified in scans of colorectal cancer risk with respect to the outcome of colorectal cancer survival has yielded null results. 49 Colorectal cancer incidence and colorectal cancer progression and prognosis, although related, are independent outcomes, 
and we expect that the opposite may also be true-variants identified as important for disease progression may not be equally important for disease initiation. Inflammation is known to be important for initiation, but an important role also exists for inflammation in the regulation of cellular adhesion, disintegration of the extracellular matrix, and angiogenesis, which all affect tumor invasion and metastatic potential. Our results are novel, and further studies, particularly genome-wide scans, investigating the role of genetic variation in colorectal cancer prognosis may in fact identify new loci that were not identified in scans related to disease incidence.
The associations observed here may be due in part to an association between variation in the investigated genes and the stage at which colorectal cancer is diagnosed in patients.
Inherited genetic variation is a lifelong exposure, such that polymorphisms in a given individual may alter the rate at which disease develops and progresses, resulting in colorectal cancer diagnosis at a different stage of disease. If genetic variation alters survival after a diagnosis of colorectal cancer because it alters the stage at which the tumor is diagnosed, then stage may be considered part of the "causal pathway" between genetic variation and colorectal cancer survival. This is consistent with our observations, in that adjustment for stage attenuated the magnitude of observed associations for certain SNPs in PTGS-1, and patients with minor alleles for these SNPs were more likely to present with advanced stage of disease at diagnosis. replication in future studies. 36 Utilizing a standard FDR level has been suggested to be a potentially more useful method for allowing a uniform comparison of genetic epidemiology studies.
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Additional study strengths include accurate exposure measurement and complete and standardized outcome follow-up for all study participants. The potential for population stratification was examined by restriction of analyses to Caucasian patients only, with no differences in associations observed. The average time between diagnosis and study enrollment for cases in the Seattle Colon CFR was 8 months (95% CI: 3-13), such that our study did not suffer from long lag times between diagnosis and enrollment that can result in patient loss, particularly loss of patients with more advanced stages of disease, and limit generalizability of results. This is one of the first investigations of inherited genetic variation and colorectal cancer survival; additional studies with larger sample sizes and more ethnically diverse study populations are required to confirm our findings and to further characterize the specific nature of the associations between the identified genes and patient survival. Future studies should also include more detailed treatment information. We were only able to consider first-line treatment data in our analysis; although this data did not alter observed associations, the examination of more detailed treatment information could shed light on potential interactions between inherited genetic variation and treatment responses. Finally, patients originated from a population-based cancer registry, but the design of the parent genetic association studies required that each colorectal cancer patient had to have a sibling that was not affected by colorectal cancer to participate. The minor allele frequencies observed in this study population were higher than would be expected in a population that was not enriched with a first-degree family history of colorectal cancer. Although the direction of the potential bias introduced by this selection is Very little is known about the role of genetic variation in altering patient survival after a diagnosis of colorectal cancer. Our findings suggest that variation in genes involved in crucial inflammatory pathways may be important for disease prognosis. This study begins to shed light on specific pro-inflammatory genes that should be investigated further; both PTGS-1 (COX-1) and IκBKβ should be top priority genes for inclusion in future studies of colorectal cancer outcomes. 
